免疫疗法耐药性：答案就在前方——而不是在我们面前。
Immunotherapy resistance: the answers lie ahead - not in front - of us.
机构信息
Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Unit Number 1484, Houston, TX 77030 USA.
Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Unit Number 1484, Houston, TX 77030 USA.
出版信息
J Immunother Cancer. 2017 Feb 21;5:10. doi: 10.1186/s40425-017-0212-y. eCollection 2017.
Abstract
Mechanisms of innate and adaptive resistance to checkpoint blockade immunotherapy are under intense investigation with a view to broadening the therapeutic potential of this form of treatment. In a recent manuscript by Zaretsky and colleagues, mutational events were identified that effectively crippled ongoing immunotherapy responses in patients treated with anti-PD-1 therapy. These results are discussed in the light of other recent and ongoing research efforts exploring both mutational and non-mutational resistance mechanisms, highlighting the critical translational importance of longitudinal tumor sampling.
摘要
目前正在深入研究先天和适应性抵抗检查点阻断免疫疗法的机制，以期扩大这种治疗形式的治疗潜力。在 Zaretsky 及其同事最近的一篇论文中，鉴定了导致接受抗 PD-1 治疗的患者的免疫治疗反应失效的突变事件。这些结果结合其他最近和正在进行的研究工作（探索突变和非突变抵抗机制）进行了讨论，突出了纵向肿瘤采样的关键转化重要性。
相似文献
1
Immunotherapy resistance: the answers lie ahead - not in front - of us.
J Immunother Cancer. 2017 Feb 21;5:10. doi: 10.1186/s40425-017-0212-y. eCollection 2017.
2
Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors.
Proc Natl Acad Sci U S A. 2016 Nov 29;113(48):E7769-E7777. doi: 10.1073/pnas.1607836113. Epub 2016 Nov 11.
3
Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.
Clin Cancer Res. 2017 Sep 1;23(17):5024-5033. doi: 10.1158/1078-0432.CCR-16-0698. Epub 2017 May 16.
4
Recent advances in the clinical development of immune checkpoint blockade therapy.
Cell Oncol (Dordr). 2019 Oct;42(5):609-626. doi: 10.1007/s13402-019-00456-w. Epub 2019 Jun 14.
5
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29.
6
Potential Predictive Value of and Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma.
Clin Cancer Res. 2017 Jun 15;23(12):3012-3024. doi: 10.1158/1078-0432.CCR-16-2554. Epub 2016 Dec 30.
7
Landscape of PD-1/PD-L1 Regulation and Targeted Immunotherapy.
Chin Med Sci J. 2018 Sep 20;33(3):174-182. doi: 10.24920/21804.
8
The Roles of microRNAs in Regulating the Expression of PD-1/PD-L1 Immune Checkpoint.
Int J Mol Sci. 2017 Nov 27;18(12):2540. doi: 10.3390/ijms18122540.
9
Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade.
J Clin Invest. 2018 Oct 1;128(10):4654-4668. doi: 10.1172/JCI99317. Epub 2018 Sep 10.
10
PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy.
J Clin Invest. 2018 Apr 2;128(4):1413-1428. doi: 10.1172/JCI98047. Epub 2018 Mar 5.
引用本文的文献
1
Improvement of the Anticancer Efficacy of PD-1/PD-L1 Blockade: Advances in Molecular Mechanisms and Therapeutic Strategies.
MedComm (2020). 2025 Jul 15;6(8):e70274. doi: 10.1002/mco2.70274. eCollection 2025 Aug.
2
Open-label, phase Ia study of STING agonist BI 1703880 plus ezabenlimab for patients with advanced solid tumors.
Future Oncol. 2025 Jan;21(2):195-200. doi: 10.1080/14796694.2024.2441107. Epub 2025 Jan 16.
3
TGF-β mRNA levels in circulating extracellular vesicles are associated with response to anti-PD1 treatment in metastatic melanoma.
Front Mol Biosci. 2024 Apr 3;11:1288677. doi: 10.3389/fmolb.2024.1288677. eCollection 2024.
4
Optimum fractionation of radiation to combine PD-1 blockade.
MedComm (2020). 2023 May 16;4(3):e271. doi: 10.1002/mco2.271. eCollection 2023 Jun.
5
Construction of patient-derived tumor models to evaluate anticancer agents and cancer immunotherapy.
Oncol Lett. 2021 May;21(5):406. doi: 10.3892/ol.2021.12667. Epub 2021 Mar 22.
6
Salvage Therapy With Multikinase Inhibitors and Immunotherapy in Advanced Adrenal Cortical Carcinoma.
J Endocr Soc. 2020 Jun 9;4(7):bvaa069. doi: 10.1210/jendso/bvaa069. eCollection 2020 Jul 1.
7
Molecular Mechanisms and Countermeasures of Immunotherapy Resistance in Malignant Tumor.
J Cancer. 2019 Apr 20;10(7):1764-1771. doi: 10.7150/jca.26481. eCollection 2019.
8
Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease.
J Immunother Cancer. 2018 May 14;6(1):35. doi: 10.1186/s40425-018-0342-x.
9
In vitro immunotherapy potency assays using real-time cell analysis.
PLoS One. 2018 Mar 2;13(3):e0193498. doi: 10.1371/journal.pone.0193498. eCollection 2018.
10
PD-L1 expression in colorectal cancer defines three subsets of tumor immune microenvironments.
Oncotarget. 2018 Jan 12;9(9):8584-8596. doi: 10.18632/oncotarget.24196. eCollection 2018 Feb 2.
本文引用的文献
1
Cancer Genomics in Clinical Context.
Trends Cancer. 2015 Sep;1(1):36-43. doi: 10.1016/j.trecan.2015.07.010. Epub 2015 Sep 28.
2
Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade.
Cell. 2016 Dec 1;167(6):1540-1554.e12. doi: 10.1016/j.cell.2016.11.022.
3
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.
Cancer Discov. 2017 Feb;7(2):188-201. doi: 10.1158/2159-8290.CD-16-1223. Epub 2016 Nov 30.
4
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.
N Engl J Med. 2016 Sep 1;375(9):819-29. doi: 10.1056/NEJMoa1604958. Epub 2016 Jul 13.
5
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.
Cancer Discov. 2016 Aug;6(8):827-37. doi: 10.1158/2159-8290.CD-15-1545. Epub 2016 Jun 14.
6
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.
JAMA. 2016 Apr 19;315(15):1600-9. doi: 10.1001/jama.2016.4059.
7
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.
Cell. 2016 Mar 24;165(1):35-44. doi: 10.1016/j.cell.2016.02.065. Epub 2016 Mar 17.
8
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.
Nat Commun. 2016 Feb 17;7:10501. doi: 10.1038/ncomms10501.
9
Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance.
Cell. 2015 Sep 10;162(6):1271-85. doi: 10.1016/j.cell.2015.07.061.
10
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma.
Science. 2015 Oct 9;350(6257):207-211. doi: 10.1126/science.aad0095. Epub 2015 Sep 10.
Zotero 插件